Tulmimetostat clinical trials
Also written DZR123.
How each study uses tulmimetostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tulmimetostat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Novartis Pharmaceuticals (3) · Washington University School of Medicine (1) · Lan Coffman (1) · VA Office of Research and Development (1)
Often tested with
Tested in the same studies.
Luxdegalutamide (1) · Darolutamide (1) · Abiraterone (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tulmimetostat.
- Feb 2027Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary SyndromePhase 1 · Washington University School of Medicine
Studies
Open first, then newest update. How each study uses tulmimetostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07206056Written as Tulmimetostat DL1 QD
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07190300Written as Tulmimetostat
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingPhase 1/2Novartis PharmaceuticalsNCT04104776Written as Tulmimetostat
- CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian CancerRecruitingPhase 1Lan CoffmanNCT05942300Written as CPI-0209
- EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung CancerRecruitingPhase 1/2VA Office of Research and DevelopmentNCT05467748Written as Tulmimetostat
- Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary SyndromeActive, not recruitingPhase 1Washington University School of MedicineNCT05944562Written as Tulmimetostat
Codes
What other systems call tulmimetostat · ClinicalTrials.gg INT017501
- UNII (FDA) OUQ4N85Z0BTULMIMETOSTATConfirmed FDA, Wikidata
- Wikidata Q134877595tulmimetostatConfirmed FDA, Wikidata
- NCI Thesaurus C167347TulmimetostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OUQ4N85Z0B | TULMIMETOSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q134877595 | tulmimetostat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C167347 | Tulmimetostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.